<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Pegaptanib; Ranibizumab; Verteporfin; Age-related macular degeneration; Macular degeneration, age-related" /><meta name="IX" content="Pegaptanib; Ranibizumab; Verteporfin; Age-related macular degeneration; Macular degeneration, age-related" /><title>Subfoveal choroidal neovascularisation: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP7164-subfoveal-choroidal-neovascularisation.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP7164-subfoveal-choroidal-neovascularisation.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP7164-subfoveal-choroidal-neovascularisation.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP6804-eye.htm">11 Eye</a> &gt; <a href="PHP7061-miscellaneous-ophthalmic-preparations.htm">11.8 Miscellaneous ophthalmic preparations</a> &gt; <a href="PHP7140-ocular-diagnostic-and-peri-operative-preparations-and-photodynamic-treatment.htm">11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP7162-nepafenac.htm" title="Previous: NEPAFENAC">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP7167-pegaptanib-sodium.htm" title="Next: PEGAPTANIB SODIUM">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a305011.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pegaptanib Sodium (EENT)</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Eye, Ear, Nose, and Throat (EENT) Preparations 52:00 &gt; EENT Drugs, Miscellaneous 52:92</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a306023.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ranibizumab (EENT)</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Eye, Ear, Nose, and Throat (EENT) Preparations 52:00 &gt; EENT Drugs, Miscellaneous 52:92</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a300012.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Verteporfin (EENT)</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Eye, Ear, Nose, and Throat (EENT) Preparations 52:00 &gt; EENT Drugs, Miscellaneous 52:92</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/14529-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Verteporfin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: V &gt; Interactions of Verteporfin</p></div></li></ul><ul><li><h3>British National Formulary (7)</h3></li><li><a href="PHP7167-pegaptanib-sodium.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">PEGAPTANIB SODIUM</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 11 Eye &gt; 11.8 Miscellaneous ophthalmic preparations &gt; 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment &gt; Subfoveal choroidal neovascularisation</p></div></li><li><a href="PHP7168-macugen.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Macugen®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 11 Eye &gt; 11.8 Miscellaneous ophthalmic preparations &gt; 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment &gt; Subfoveal choroidal neovascularisation &gt; PEGAPTANIB SODIUM</p></div></li><li><a href="PHP7169-ranibizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">RANIBIZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 11 Eye &gt; 11.8 Miscellaneous ophthalmic preparations &gt; 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment &gt; Subfoveal choroidal neovascularisation</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22pegaptanib%22%22ranibizumab%22%22verteporfin%22%22age-related+macular+degeneration%22%22macular+degeneration,+age-related%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (7)</a></li></ul><ul><li><h3>Dietary Supplements (7)</h3></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c05.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Antioxidants</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c18.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Carotenoids</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; C</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c39.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Folic acid</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; F</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22pegaptanib%22%22ranibizumab%22%22verteporfin%22%22age-related+macular+degeneration%22%22macular+degeneration,+age-related%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (7)</a></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/14529-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Verteporfin</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/21147-b.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pegaptanib Sodium</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/21260-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ranibizumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/07068.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pegaptanib Sodium</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; P &gt; PE</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/08108.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ranibizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; R &gt; RA</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09967.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Verteporfin</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; V &gt; VE</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Subfoveal choroidal neovascularisation</h1><?highlighter on?><div id="pC" class="jN"><p id="PHP7165"><strong>Pegaptanib</strong> and <strong>ranibizumab</strong> are vascular endothelial growth factor inhibitors licensed for the treatment of neovascular (wet) age-related macular degeneration. Ranibizumab is also licensed for the treatment of visual impairment due to diabetic macular oedema or macular oedema secondary to branch or central retinal vein occlusion. Ranibizumab can be administered concomitantly with laser photocoagulation for the treatment of diabetic macular oedema and for macular oedema secondary to branch retinal vein occlusion. They are given by intravitreal injection by specialists experienced in the management of this condition.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (May 2007) that ranibizumab (<em>Lucentis</em>®) is accepted for use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration. The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (October 2011) that ranibizumab (<em>Lucentis</em>®) is accepted for restricted use within NHS Scotland for the treatment of macular oedema secondary to central retinal vein occlusion.</p><div id="PHP7166" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012)</h3><p>Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:</p><ul><li><p>the best corrected visual acuity is between 6/12 and 6/96;</p> </li><li><p>there is no permanent structural damage to the central fovea;</p> </li><li><p>the lesion size is less than or equal to 12 disc areas in greatest linear dimension;</p> </li><li><p>there is evidence of recent disease progression;</p> </li><li><p>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</p> </li></ul><p>Ranibizumab should only be continued in patients who maintain adequate response to therapy.</p><p>Pegaptanib is not recommended for the treatment of wet age-related macular degeneration; patients currently receiving pegaptanib for any lesion type can continue therapy until they and their specialist consider it appropriate to stop.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Ranibizumab for the treatment of diabetic macular oedema (November 2011)</h3><p>Ranibizumab is <strong>not</strong> recommended for the treatment of visual impairment due to diabetic macular oedema.</p></div><p><strong>Verteporfin</strong> is licensed for use in the photodynamic treatment of age-related macular degeneration associated with predominantly classic subfoveal choroidal neovascularisation <em>or</em> with pathological myopia (see NICE guidance below). Following intravenous infusion, verteporfin is activated by local irradiation using non-thermal red light to produce cytotoxic derivatives. Only specialists experienced in the management of these conditions should use it.</p><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Photodynamic therapy for wet age-related macular degeneration (September 2003)</h3><p>Photodynamic therapy is recommended for wet age-related macular degeneration with a confirmed diagnosis of classic (no occult) subfoveal choroidal neovascularisation and best-corrected visual acuity of 6/60 or better.</p><p>Photodynamic therapy is <strong>not</strong> recommended for wet age-related macular degeneration with predominantly classic but partly occult subfoveal choroidal neovascularisation <em>except</em> in clinical studies.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP7167-pegaptanib-sodium"><a href="PHP7167-pegaptanib-sodium.htm" title="PEGAPTANIB SODIUM">PEGAPTANIB SODIUM</a></li><li id="_PHP7169-ranibizumab"><a href="PHP7169-ranibizumab.htm" title="RANIBIZUMAB">RANIBIZUMAB</a></li><li id="_PHP7171-verteporfin"><a href="PHP7171-verteporfin.htm" title="VERTEPORFIN">VERTEPORFIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP7162-nepafenac.htm">Previous: NEPAFENAC</a> | <a class="top" href="PHP7164-subfoveal-choroidal-neovascularisation.htm#">Top</a> | <a accesskey="]" href="PHP7167-pegaptanib-sodium.htm">Next: PEGAPTANIB SODIUM</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>